The Abbreviated Donor Questionnaire Update from AABB Donor History Task Force to BPAC March 2005 Debra Kessler RN, MS Task Force Chair.

Slides:



Advertisements
Similar presentations
“... providing timely, accurate, and useful statistics in service to U.S. agriculture.” Using Mixed Methods to Evaluate Survey Questionnaires Heather Ridolfo,
Advertisements

U.S. Food and Drug Administration Notice: Archived Document. The content in this document is provided on the FDA’s website for reference purposes only.
Draft Guidance for Industry: Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob.
Development of Guidance Documents Jennifer Scharpf, M. P. H
Adapting AABB Donor Regulation at KCBB. Why? Blood safety starts by bleeding safe Blood donors “Safe Blood starts with me” BTS need to Implement adequate.
Public Workshop: Quarantine Release Errors in Blood Establishments September 13, 2011 QREs Past, Present and Future Sheryl A. Kochman Deputy Director Division.
Recently Issued OHRP Documents: Guidance on Subject Withdrawal and Draft Revised FWA Secretary’s Advisory Committee on Human Research Protections October.
Columbia University IRB IRB 101 September 21, 2005 George Gasparis, Executive Director, CU IRB Asst. V.P. and Sr. Asst. Dean for Research Ethics.
Enhancing HIV/AIDS Surveillance in California California Department of Public Health Office of AIDS Guide for Health Care Providers.
Unit 4: Monitoring Data Quality For HIV Case Surveillance Systems #6-0-1.
THE ADVANCED TECHNOLOGY ENVIRONMENTAL AND ENERGY CENTER (ATEEC) Summative External Evaluation July 1, 2013 – June 30, 2014 PRELIMINARY OUTLINE.
 Department of Family and Children Services, Santa Clara County  San Jose State University School of Social Work  Santa Clara County Children’s Issue.
NOSOCOMIAL INFECTION SURVEILLANCE METHODS Masud Yunesian, M.D., Epidemiologist.
The Redesigned Donor History Questionnaire: The Abbreviated Donor Questionnaire Report of the Task Force to the FDA Blood Products Advisory Committee December.
Prevalence and risk relationships of tattoo, acupuncture and skin/body piercing histories among American Red Cross blood donors Sharyn Orton, MSPH, PhD.
Is this Research? Exempt? Expedited?
Donor Selection Criteria Dr. Mindy Goldman Transfusion Medicine Residents May 24, 2011.
By Garland Land NAPHSIS Executive Director. Performance Measures Committee Dorothy Harshbarger, Alabama Dorothy Harshbarger, Alabama Barry Nangle, Utah.
FDA Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components.
National Death Index: Monitoring the Slippery Slope Lou Saadi, Ph.D. Kansas NAPHSIS Annual Meeting, 2007 Salt Lake City, Utah.
Mary Ann Laviolette, Ethics Coordinator Ottawa Hospital Research Ethics Board (OHREB) and University of Ottawa Research Ethics Board (HREB)
Reentry for Donors Deferred Based on Anti-HBc Test Results November 3, 2005 BPAC Meeting FDA/CBER/OBRR/DETTD.
Evaluating Tuberculosis Surveillance and Action in an Urban and Rural Setting Kristine Lykens, Ph.D. In collaboration with Anita Kurian, MPH, MBBS Patrick.
Capability Cliff Notes Series PHEP Capability 3—Emergency Operations Coordination What Is It And How Will We Measure It? For sound, click on the megaphone.
Fundamentals of Evaluation for Public Health Programs ROBERT FOLEY, M.ED. NIHB TRIBAL PUBLIC HEALTH SUMMIT MARCH 31,
ICH V1 An FDA Update Min Chen, M.S., RPh Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.
Procedures and Forms 2008 FRCC Compliance Workshop April 8-9, 2008.
Challenges in evaluating and changing donor criteria Dr. Mindy Goldman Transfusion Medicine Residents April 30, 2008.
Planned Emergency Research Exception from Informed Consent Requirements September 2007.
Approval Criteria for Assays for Testing Blood Donors for West Nile Virus Robin Biswas, M.D. CBER, FDA Blood Products Advisory Committee Meeting March.
Revision Process for the PHS Guideline for Reducing HIV, HBV and HCV Transmission through Solid Organ Transplantation Matthew J. Kuehnert, M.D. Office.
Components of HIV/AIDS Case Surveillance: Case Report Forms and Sources.
1 Department of Medical Assistance Services Stakeholder Advisory Committee June 25, 2014 Gerald A. Craver, PhD
Federal Aviation Administration 14 CFR Part 147 Aviation Advisory Committee Working Group Training Updates Presented to: World Aviation Training Symposium.
Module 3: Informed Consent. This training session contains information regarding: Documenting consent Documenting consent Conducting informed consent.
July 2008 CPS2 Waiver SDT Technical Workshop for Draft BAL-001-TRE-01 Judith A. James Reliability Standards Manager TRE.
Module 5: Data Collection. This training session contains information regarding: Audit Cycle Begins Audit Cycle Begins Questionnaire Administration Questionnaire.
On-line briefing for Program Directors and Staff 1.
Cluster Interview Template Updated 04/2013. Introduction to the Training ● The slides will first show a picture of the section of the template that will.
Improving Eligibility Documents November, Improving Data Collection The State Office of AIDS (OA) is now working with providers to improve the quality.
The NCI Central IRB Initiative Third Annual Medical Research Summit Washington, D.C. March 2003.
Abbreviated Donor History Questionnaire: Background and Introduction Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee March 2005.
DODAC and DSaRM Advisory Committee August 1, 2007 Pregnancy Registry and Root Cause Analysis Cynthia Kornegay, Ph.D. Division of Drug Risk Evaluation Office.
Revised Recommendations for the Assessment of Donor Suitability: West Nile Virus Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee Meeting.
Evaluation Plan Steven Clauser, PhD Chief, Outcomes Research Branch Applied Research Program Division of Cancer Control and Population Sciences NCCCP Launch.
Minimizing the Risks of TSE Agents in Human Tissues Melissa A. Greenwald, M.D. Division of Human Tissues Office of Cellular, Tissue and Gene Therapies;
HHS Secretary’s Advisory Committee on Blood Safety and Availability Summary for FDA’s BPAC July 2010 Jerry A. Holmberg, Ph.D. Senior Advisor for Blood.
Unit 9: Evaluating a Public Health Surveillance System #1-9-1.
Payer User Group Webinar – 7/31/2014. Agenda Welcome (5 minutes) ◦Opening Comments/ Review ◦Meeting Goals Chapter 243 Changes (25 minutes) ◦Clarification.
Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection - Update - Alan E. Williams, Ph.D. Director,
Deferral of Blood and Plasma Donors for History of Transfusion in BSE Countries of Europe Alan E. Williams, Ph.D. Director, Division of Blood Applications.
Commission on Accreditation for Respiratory Care Allen N. Gustin Jr., MD, FCCP Chair, CoARC Accreditation Policies/Standards/Bylaws Committee Update on.
CAA Options: Collection of Evidence CTE Connection December 8, 2006 Rod Duckworth, Director of Career and Technical Education OSPI.
DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.
FDA’s vCJD Risk Communication on US Plasma- Derived Factor VIII and UK Plasma-Derived Factor XI BPAC April 27, 2007 Mark Weinstein, Ph.D. FDA, Center for.
Karen Cheung, MPH, Pamela Luna, DrPH, MST, Sarah Merkle, MPH American Evaluation Association Annual Meeting November 11, 2009 The findings and conclusions.
Component D: Activity D.3: Surveys Department EU Twinning Project.
Bad Blood? An Investigation of the MSM Ban on Blood Donation Lauren Lacy Abstract In 1983, the Food and Drug Administration (FDA), responding to the AIDS.
CBER Current Considerations for Blood Donor Screening for West Nile Virus Pradip N. Akolkar, Ph.D. Maria Rios, Ph.D. DETTD, OBRR Blood Products Advisory.
Results Methods A Five-Year Snapshot of Our Hereditary Hemochromatosis Program: A Work in Progress P Davenport 1, D Echols 1, J Giacoletti 1, L Sutor 1,2,
Division of HIV/AIDS Managing Questionnaire Development for a National HIV Surveillance Survey, Medical Monitoring Project Jennifer L Fagan, Health Scientist/Interview.
Conditional IRB Approval
Observational Study Working Group
Evaluation Report: April 1, 2015 – March 31, 2016
Revisions to Pediatric Emergency Membership Exception
Overview of the FEPAC Accreditation Process
OPTN/UNOS Kidney Transplantation Committee
HRA User Satisfaction Report
Alignment of Part 4B with ISAE 3000
Alignment of Part 4B with ISAE 3000
Presentation transcript:

The Abbreviated Donor Questionnaire Update from AABB Donor History Task Force to BPAC March 2005 Debra Kessler RN, MS Task Force Chair

2 Donor History Questionnaire In 2000 the process to redesign the blood donor screening questionnaire began Initiated by FDA Extensive collaborative effort by numerous stakeholders Groundbreaking approach to design First time a blood screening document has been systematically evaluatedFirst time a blood screening document has been systematically evaluated

3 DHQ Overview The old Uniform Donor History Questionnaire (UDHQ) was a very different document from the current DHQ. Questions were complex, included compound elements and did not follow any identifiable order of time frames.

4 The Task Force made many changes in creating the new DHQ: –eliminated a number of questions that were not required by FDA or AABB – broke up compound questions – simplified language –restructured the format into time periods that begin at the present and go backwards in time. DHQ Overview, con’t

5 Changes were made with input of experts in the field of questionnaire development and reading comprehension. Focus groups were used to review the new questions Individual cognitive interviews by NCHS were performed to validate that the questions elicited the information intended.

6 Donor History Questionnaire: Recent History June Blood Products Advisory Committee Unanimously endorsed the full length Donor History Questionnaire. April FDA Draft Guidance for Industry: Acceptable Full- Length Donor History Questionnaire and Accompanying Materials for Use In Screening Human Donors of Blood and Blood Components.

7 Donor History Questionnaire: Recent History December DHTF Submitted responses to comments to the docket with related revisions to the DHQ (v.1.1) and associated materials Currently The DHQ is in use in many collection sites Next steps - AABB receive any FDA feedback on revisions AABB to issue revised materials as version 1.1 FDA to issue final guidance on full length DHQ

Abbreviated Donor History Questionnaire (aDHQ)

9 Abbreviated Questionnaire for Frequent Donors Currently, all donors answer all questions at every donation, including non-repeatable events What Abbreviated Questionnaire Does: Eliminates non-repeatable event questions Identifies recent changes in health, travel, behavior Retains questions about risk-associated activities that might have changed since last donation

10 Precedent –Abbreviated screening document approved for Blood Center of Iowa in 1999 –Abbreviated screening document approved for Blood Systems in 2002 aDHQ

11 aDHQ-What do we hope to accomplish? SafetySafety Safety and efficacy equivalent to DHQ SatisfactionSatisfaction Increase donor satisfaction AvailabilityAvailability Possibly increase availability of blood

12 Equivalent safety to DHQ –The aDHQ is based on the full length DHQ which is a validated document –Testing of aDHQ capture approach for recent changes in health status was performed on 4 subjects by one-on-one cognitive interview when the initial DHQ evaluation was conducted “Since your last donation have you had any new medical problems, diagnoses or treatments including vaccinations?”

13 Equivalent safety to DHQ, cont. Capture question one-on-one cognitive interviews: –Performed on only 4 persons due to lack of resources. While this was not a full large-scale test, preliminary findings generated optimism that the approach is worth pursuing further. –The event not reported was a miscarriage Pregnancy in past 6 weeks is not rolled into the medical capture questions. It continues to be asked specifically on the aDHQ.

14 Equivalent safety to DHQ –Increased donor focus on recent risk behaviors and activities “behavioral risk screening needs to be optimized to query donors about factors that best predict recent infection.” from Blood Safety in the New Millennium, 2001 Alan Williams, PhD and Sharyn Orton, MSPH, PhD

15 Equivalent safety to DHQ –Increased donor attention by reducing time required to complete screening

16 Increased availability of blood? –Increased donor satisfaction –Decrease phenomenon of “lapsed donors” –Increased frequency of donation

17 –Definition of Frequent Donor Successfully complete full-length DHQ (DHQ) at least twice At least one donation within previous 6 month period newvalidated Rationale: The donor will answer all of the new validated screening questions at least twice. Anecdotal evidence indicates that donors may remember information at the second donation that they did not remember at the first donation. However, this is less likely to occur after a second experience with the questions. Which donors will use the aDHQ

18 –Validated DHQ basis for aDHQ –Question-by-question consideration Delete questions for single risk in past “From 1980 through 1996, were you a member of the U.S. military, a civilian military employee, or a dependent of a member of the U.S. military?” –Consolidate travel into a single capture question about recent travel –Consolidate medical questions by use of 2 capture questions –HIV and Hepatitis risk questions remain intact Development of aDHQ

19 BPAC discussion re: aDHQ Dec 11, 2003 Question - “Does current knowledge support the use of the AABB DHQ abbreviated questionnaire as an alternative to the current screening process for appropriately selected donors?” –Yes 10 – No 2 – Abstain 1

20 Nevertheless FDA requested that the Task Force develop some kind of pre-implementation study to compare the full length and abbreviated donor forms as related to medical capture questions.

aDHQ Study

22 aDHQ Study Development Team Subgroup of AABB DHTF –Representatives from: AABB FDA NCHS Blood Centers

23 aDHQ Study Objectives Determine whether two medical capture questions identify deferrable risks as well as the full-length questionnaire. Compare responses to the two medical capture questions with responses to the questions they cover in the full-length questionnaire. Identify reasons for discrepancies between answers provided to the capture questions and the full-length questionnaire using cognitive interviews

24 aDHQ Medical Capture Questions Since your last donation have you – Had any new medical problems or diagnoses? – Had any new medical treatments?

25 DHQ Questions rolled into capture questions Are you –Currently taking an antibiotic? –Currently taking any other medication for an infection? In the past 12 months have you –Had a blood transfusion? –Had a transplant such as organ, tissue, or bone marrow? –Had a graft such as bone or skin? –Had or been treated for syphilis or gonorrhea?

26 DHQ Questions rolled into capture questions Have you EVER –Had a positive test for the HIV/AIDS virus? –Used clotting factor concentrates? –Had hepatitis? –Had malaria? –Had Chagas’ disease? –Had babesiosis? –Received a dura mater (or brain covering) graft? –Had any type of cancer, including leukemia? –Had any problems with your heart or lungs? –Had a bleeding condition or a blood disease?

27 Study Sites New York Blood Center Hoxworth Blood Center Gulf Coast Regional Blood Center Mississippi Valley Regional Blood Center ARC, Lewis & Clark Region –Centers selected to represent mixed U.S. geographic areas

28 Study Size 250 donors from each of the Blood Centers who meet the definition of frequent donor. Total sample =1250 –the final sample will include donors from the full range of the 6 month interval since their last donation.

29 Study Process Donor will be enrolled by designated staff and give consent Donor will fill out aDHQ first and return it to study personnel. Donor will then fill out standard full length DHQ. Study personnel will evaluate for discordant responses.

30 Study Process, con’t During study the donor’s eligibility to donate will be based on BOTH questionnaires If discordant responses are found, donor will undergo cognitive interview on site or as soon as possible via phone. Interviews will be audio-taped.

31 Cognitive Interviews Each center will provide 2 staff members for cognitive interview training by NCHS staff. Blood center staff selected will be those with skills that lend themselves to cognitive interviewing (eg. donor counselors)

32 Data Evaluation Audio tapes will be transcribed The transcription and, if needed, audio tape will be evaluated by NCHS Demographic information and discordant responses will be entered into a database for evaluation.

33 Study Timeline May 3, NCHS to train blood center staff in cognitive interviewing June-Dec, execute protocol Jan transcription of cognitive interviews Feb-Mar, NCHS analysis of cognitive interviews May Submission of results to FDA

34 Cost Burden Cost to AABB –Interviewer travel for training by NCHS –Interviewer training and analysis of cognitive interviews by NCHS –Study Administrator –Data Entry Blood Center –Study personnel time –Materials

35 Conclusions: aDHQ developed at the request of FDA Received BPAC endorsement in 2003 At the request of FDA, the Task Force has developed a study for aDHQ This is NOT intended to be a epidemiologic study The emphasis for evaluation is on the cognitive interviews Post implementation evaluation will add additional data